Latest News and Press Releases
Want to stay updated on the latest news?
-
MORRISVILLE, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an overview and...
-
MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of...
-
- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery- Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder- Improved financial position...
-
MORRISVILLE, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that on May 7, 2021, it resubmitted its New Drug Application (NDA) for LIQ861 for the...
-
MORRISVILLE, N.C., May 06, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2021 financial results on Thursday, May 13, 2021. The...
-
RESEARCH TRIANGLE PARK, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it has entered into a common stock purchase agreement with certain...
-
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia, will provide an...
-
Addressable market for generic Treprostinil Injection more than doublesFDA cleared 510(k) for RG 3ml Medication Cartridge for use with CADD-MS® 3 pump RESEARCH TRIANGLE PARK, N.C., March 30, 2021...
-
- Integrated RareGen (now known as Liquidia PAH) to establish commercial presence in PAH- Clarified path towards submitting response to CRL for LIQ861 in mid-2021- Reducing net annual spending more...
-
RESEARCH TRIANGLE PARK, N.C., March 09, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that 2020 financial results will be reported on Tuesday, March 23, 2021. The...